Inspire Medical CEO on Improving Patient Outcomes

Tim Herbert, Founder, Chairman, President and CEO of publicly traded Inspire Medical Systems, discusses the company's breakthrough technology that helps people suffering from obstructive sleep apnea, as well as the company's strong quarterly earnings amid headwinds facing the broader health care industry. Tim speaks with Tim Stenovec and Emily Graffeo on Bloomberg Businessweek Daily. (Source: Bloomberg)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

11 minutes ago

• Yahoo

Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation (NASDAQ:SRRK) is one of the best-performing stocks on Thursday. Scholar Rock jumped by 16.6 percent on Wednesday to close at $36.32 apiece as investor sentiment was bolstered by the positive results from the second phase of its weight loss drug trial. In a statement, Scholar Rock Holding Corporation (NASDAQ:SRRK) said the trial, which aims to assess its drug candidate apitegromab's combination with tirzepatide, was generally well tolerated, leading to higher quality weight loss as compared with taking tirzepatide alone. According to Scholar Rock Holding Corporation (NASDAQ:SRRK), apitegromab therapy in combination with tirzepatide resulted in the preservation of 4.2 pounds of lean mass compared with tirzepatide alone. 'While this is an exciting development for our platform, we remain focused on preparing for the launch of apitegromab, and following its potential approval in SMA, we look forward to studying it in a range of neuromuscular diseases with high unmet need,' said Scholar Rock Holding Corporation (NASDAQ:SRRK) President and CEO Akshay Vaishnaw, adding that he was looking forward to exploring its potential in various rare, severe debilitating neuromuscular disorders. A scientist holding a flask of liquid in a laboratory, highlighting the research and discoveries of new treatments. 'We remain on track to file an IND application for SRK-439 in the second half of this year to support the first in human study,' he said. While we acknowledge the potential of SRRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wall Street Journal

14 minutes ago

• Wall Street Journal

Trump Says He's Nearing a Possible Deal With Harvard

President Trump said his administration was 'working closely' with Harvard University and could announce a deal within the next week. The White House and Harvard have been locked in battle since late March. Trump has pulled billions in federal funds over antisemitism and DEI concerns, tried to block Harvard's ability to enroll international students and threatened its tax-exempt status. Harvard has sued the administration, saying the government has violated its First Amendment rights.

New York Times

16 minutes ago

• New York Times

People With Severe Diabetes Are Cured in Small Trial of New Drug

A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need much lower doses. The experimental treatment, called zimislecel and made by Vertex Pharmaceuticals of Boston, involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. The new islet cells were infused and reached the pancreas, where they took up residence. The study was presented Friday evening at the annual meeting of the American Diabetes Association and published online by The New England Journal of Medicine. 'It's trailblazing work,' said Dr. Mark Anderson, professor and director of the diabetes center at the University of California in San Francisco. 'Being free of insulin is life changing,' added Dr. Anderson, who was not involved in the study. Vertex, like other drug companies, declined to announce the treatment's cost before the Food and Drug Administration approves it. The treatment, said Vertex spokeswoman Dee Smith, could potentially help all patients with type 1 diabetes, although they would need to weigh the risks against the benefits of possibly not needing insulin. Want all of The Times? Subscribe.